Intended for healthcare professionals


Semaglutide may provide sustained weight loss for at least four years, study reports

BMJ 2024; 385 doi: (Published 16 May 2024) Cite this as: BMJ 2024;385:q1113
  1. Elisabeth Mahase
  1. The BMJ

A new analysis of data from Novo Nordisk’s Select trial indicates that semaglutide (marketed as Wegovy) can enable patients who are overweight or obese to “achieve clinically meaningful weight loss” for at least four years, with fewer serious adverse events than placebo.1 The analysis, conducted by the manufacturer and published in Nature Medicine, examined the weight loss effects of semaglutide across a geographically and ethnically diverse population over four years. It reported that improvements were seen in men and women and in all the ethnic and age categories studied, irrespective of starting body size.

The Select trial, which ran from 2018 to 2023 and involved more than 17 600 adults from 41 countries who had pre-existing cardiovascular disease and a BMI ≥27 but no history of diabetes. Trial …

View Full Text

Log in

Log in through your institution


* For online subscription